OS

OneStream, Inc. Class A Common Stock
Inactive Not actively trading
$24.00
+0.00 (+0.00%)
Mkt Cap 2.40B
Volume 2,661,330
52W Range 16.51-29.66
Sector Technology
Beta 1.99
EPS (TTM) -0.28
P/E Ratio -65.64
Revenue (TTM) 601.93M
Rev Growth (5Y) +29.2%
EPS Growth (5Y) N/A

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022
Revenue 601.93M 489.41M 374.92M 279.32M
Net Income (50.30M) (216.20M) (28.93M) (65.47M)
EPS -0.28 -1.25 -0.85 -0.28
Free Cash Flow 95.63M 58.53M 18.68M (37.92M)
FCF / Share 0.53 0.34 0.12 -0.16
Operating CF 96.67M 61.15M 21.27M (32.94M)
Total Assets 1.03B 823.22M 361.56M 320.01M
Total Debt 14.80M 18.59M 20.03M 18.91M
Cash & Equiv 693.58M 544.17M 117.09M 14.69M
Book Value 504.71M 386.17M 106.53M 127.14M
Return on Equity -0.10 -0.56 -0.27 -0.51
OS News
Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings
Jun 23, 2026 05:00 AM · businesswire.com
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Jun 14, 2026 12:00 AM · gurufocus.com
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Jun 13, 2026 09:00 AM · gurufocus.com
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Jun 13, 2026 03:00 AM · gurufocus.com
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
Jun 13, 2026 02:00 AM · gurufocus.com
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
Jun 11, 2026 04:00 AM · gurufocus.com
WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award
Jun 10, 2026 05:02 AM · businesswire.com
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Jun 08, 2026 05:00 PM · gurufocus.com
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
Jun 02, 2026 05:00 AM · gurufocus.com
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Jun 01, 2026 08:00 AM · gurufocus.com